EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advances in vaccine development for Chlamydia trachomatis

Taylor B Poston iD

Pathogens and Disease · 2024

DOI: 10.1093/femspd/ftae017 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pathogens and Disease, 2024. Verfasst von Taylor B Poston. Beteiligte Einrichtung: Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States. Hauptthemen laut MEDLINE: Chlamydia trachomatis, Bacterial Vaccines, Chlamydia Infections, Vaccine Development. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 190 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chlamydia trachomatis is the most prevalent bacterial sexually transmitted infection globally. Antibiotic treatment is highly effective, but infection is often asymptomatic resulting in most individuals going undetected and untreated. This untreated infection can ascend to the upper female genital tract to cause pelvic inflammatory disease, tubal factor infertility, and ectopic pregnancy. Chlamydia screening and treatment programs have failed to control this epidemic and demonstrate the need for an efficacious vaccine to prevent transmission and disease. Animal models and human epidemiological data reveal that natural immunity can provide partial or short-lived sterilizing immunity. These data further demonstrate the importance of eliciting interferon gamma (IFNγ)-producing cluster of differentiation 4 (CD4) T cells (Th1 and Th1/17 cells) that can likely synergize with antibody-mediated opsonophagocytosis to provide optimal protection. These studies have guided preclinical rational vaccine design for decades and the first Phase 1 clinical trials have recently been completed. Recent advances have led to improvements in vaccine platforms and clinically safe adjuvants that help provide a path forward. This review describes vaccine models, correlates of immunity, antigen and adjuvant selection, and future clinical testing for Chlamydia vaccine development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chlamydia trachomatisBacterial VaccinesChlamydia InfectionsVaccine DevelopmentHumansAnimalsDisease Models, AnimalAdjuvants, ImmunologicFemaleTh1 Cells

Stichwörter der Autor:innen

ChlamydiaT celladjuvantantibodyvaccine

Substanzen

Bacterial VaccinesAdjuvants, Immunologic

Autor:innen und Institutionen

  • Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States.

ORCID-Profile: Taylor B Poston

Zitieren

APA

Poston, T. B. (2024). Advances in vaccine development for Chlamydia trachomatis. Pathogens and Disease. https://doi.org/10.1093/femspd/ftae017

Vancouver

Poston TB. Advances in vaccine development for Chlamydia trachomatis. Pathogens and Disease. 2024. doi:10.1093/femspd/ftae017

BibTeX
@article{Poston2024,
  author = {Poston, Taylor B},
  title = {Advances in vaccine development for Chlamydia trachomatis},
  journal = {Pathogens and Disease},
  year = {2024},
  doi = {10.1093/femspd/ftae017}
}
Kostenlos starten →